Brian Liddicoat

Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK Dependent Cell Death

Sylvain Garciaz, Andrew A Guirguis, Sebastian Muller, Fiona C Brown, Yih-Chih Chan, Ali Motazediani, Caitlin L Rowe, James A Kuzich, Kah Lok Chan, Kevin Tran, Lorey Smith, Laura MacPherson, Brian Liddicoat, Enid YN Lam, Tatiana Caneque, Marian L Burr, Veronique Litalien, Giovanna Pomilio, Mathilde Poplineau, Estelle Duprez, et al.

Journal article  |  2022  |  CANCER DISCOVERY

UNLABELLED: Cancer cell metabolism is increasingly recognized as providing an exciting therapeutic opportunity. However, a drug th..

Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax

Sylvain Garciaz, Sebastian Muller, Andew Guirguis, Fiona C Brown, Yih Chih Chan, Mathilde Paplineau, Kevin Tran, Kah-Lok Chan, Laura Mac Pherson, Brian Liddicoat, Enid YN Lam, Tatiana Caneque, Marian L Burr, Veronique Litalien, Giovanna Pomilio, Estelle Duprez, David CS Huang, Sarah-Jane Dawson, Georg Ramm, Andrew G Cox, et al.

Conference Proceedings  |  2021  |  BLOOD

Abstract Although the BCL2 inhibitor venetoclax have been transformative in the management of AML, therapeutic resi..

The old and the new: DNA and RNA methylation in normal and malignant hematopoiesis

Andrew A Guirguis, Brian J Liddicoat, Mark A Dawson

Journal article  |  2020  |  EXPERIMENTAL HEMATOLOGY

Whilst DNA cytosine methylation is the oldest and most well-studied epigenetic modification, basking in its glory days, it may be ..

Place Yours BETs in Combination Therapy

Brian J Liddicoat, Mark A Dawson

Journal article  |  2020  |  MOLECULAR CELL

Combination therapy remains the cornerstone for cancer management, and understanding how to rationally partner drugs is imperative..

Extrinsically derived TNF is primarily responsible for limiting antiviral CD8 T cell response magnitude

Kylie M Quinn, Wan-Ting Kan, Katherine A Watson, Brian J Liddicoat, Natasha G Swan, Hayley McQuilten, Alice E Denton, Jasmine Li, Weisan Chen, Lorena E Brown, David C Jackson, Patrick C Reading, Peter C Doherty, Katherine Kedzierska, Lukasz Kedzierski, Stephen J Turner, Nicole L La Gruta

Journal article  |  2017  |  PLOS ONE

TNF is a pro-inflammatory cytokine produced by both lymphoid and non-lymphoid cells. As a consequence of the widespread expression..

Protein recoding by ADAR1-mediated RNA editing is not essential for normal development and homeostasis

Jacki E Heraud-Farlow, Alistair M Chalk, Sandra E Linder, Qin Li, Scott Taylor, Joshua M White, Lokman Pang, Brian J Liddicoat, Ankita Gupte, Jin Billy Li, Carl R Walkley

Journal article  |  2017  |  GENOME BIOLOGY

BACKGROUND: Adenosine-to-inosine (A-to-I) editing of dsRNA by ADAR proteins is a pervasive epitranscriptome feature. Tens of thous..

ADAR1, inosine and the immune sensing system: distinguishing self from non-self

Brian J Liddicoat, Alistair M Chalk, Carl R Walkley

Journal article  |  2017  |  WILEY INTERDISCIPLINARY REVIEWS-COMPUTATIONAL MOLECULAR SCIENCE

The conversion of genomically encoded adenosine to inosine in dsRNA is termed as A-to-I RNA editing. This process is catalyzed by ..

RNA EDITING RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself

Brian J Liddicoat, Robert Piskol, Alistair M Chalk, Gokul Ramaswami, Miyoko Higuchi, Jochen C Hartner, Jin Billy Li, Peter H Seeburg, Carl R Walkley

Journal article  |  2015  |  SCIENCE

Adenosine-to-inosine (A-to-I) editing is a highly prevalent posttranscriptional modification of RNA, mediated by ADAR (adenosine d..

The SKI proto-oncogene enhances the in vivo repopulation of hematopoietic stem cells and causes myeloproliferative disease

Sofie Singbrant, Meaghan Wall, Jennifer Moody, Goeran Karlsson, Alistair M Chalk, Brian Liddicoat, Megan R Russell, Carl R Walkley, Stefan Karlsson

Journal article  |  2014  |  HAEMATOLOGICA

The proto-oncogene SKI is highly expressed in human myeloid leukemia and also in murine hematopoietic stem cells. However, its ope..

Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA

Anthony J Mutsaers, Alvin JM Ng, Emma K Baker, Megan R Russell, Alistair M Chalk, Meaghan Wall, Brain JJ Liddicoat, Patricia WM Ho, John L Slavin, Ankita Goradia, T John Martin, Louise E Purton, Ross A Dickins, Carl R Walkley

Journal article  |  2013  |  BONE

Osteosarcoma is the most common primary cancer of bone and one that predominantly affects children and adolescents. Osteoblastic o..